Streamex P/CF

Que fait Streamex ? BioSig Technologies, Inc. generates revenue through the commercialization of its proprietary biomedical signal processing platform, which enhances signal fidelity to extract detailed electrocardiographic and intra-cardiac data. The company focuses on providing intracardiac signal information to electrophysiologists during electrophysiology studies and cardiac catheter ablation procedures for atrial fibrillation and ventricular tachycardia. Its flagship product, the PURE EP System, is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during these medical procedures. The firm targets healthcare professionals specializing in cardiac electrophysiology, including electrophysiologists and cardiac catheter ablation specialists, who use its technology to improve diagnostic accuracy and procedural outcomes in treating heart rhythm disorders. BioSig Technologies, Inc. sells its PURE EP System to medical institutions and healthcare providers performing electrophysiology studies and ablation procedures. The company's technology is specifically designed for use during atrial fibrillation and ventricular tachycardia treatments, where precise signal analysis is critical for successful outcomes. By focusing on these high-precision medical applications, the firm serves a specialized segment of the healthcare market that requires advanced signal processing capabilities for cardiac diagnostics and treatment procedures. Streamex est l'une des entreprises les plus populaires sur Eulerpool.